1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.2.1 INCLUSIONS AND EXCLUSIONS 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION 19
FIGURE 2 WEARABLE INJECTORS MARKET, BY REGION 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
TABLE 1 STANDARD CURRENCY CONVERSION RATES 20
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21
1.7 SUMMARY OF CHANGES 21

2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
FIGURE 3 RESEARCH DESIGN 23
2.1.1 SECONDARY DATA 24
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 25
FIGURE 4 PRIMARY SOURCES 26
2.1.2.1 Key data from primary sources 27
2.1.2.2 Key industry insights 28
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (WEARABLE INJECTORS MARKET) 28
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 29
2.2 MARKET SIZE ESTIMATION 29
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 30
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC. 30
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: WEARABLE INJECTORS MARKET (2020) 31
FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE WEARABLE INJECTORS MARKET (2021-2026) 32
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 33
FIGURE 12 BOTTOM-UP APPROACH 34
FIGURE 13 TOP-DOWN APPROACH 34
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
FIGURE 14 DATA TRIANGULATION METHODOLOGY 35
2.4 MARKET RANKING ESTIMATION 36
2.5 ASSUMPTIONS FOR THE STUDY 36
2.6 RISK ASSESSMENT 37
2.7 COVID-19 HEALTH ASSESSMENT 37
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE WEARABLE INJECTORS MARKET 37

3 EXECUTIVE SUMMARY 38
FIGURE 15 WEARABLE INJECTORS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 38
FIGURE 16 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021 VS. 2026
(USD MILLION) 39
FIGURE 17 WEARABLE INJECTORS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION) 40
FIGURE 18 WEARABLE INJECTORS MARKET, BY END USER, 2021 VS. 2026
(USD MILLION) 41
FIGURE 19 GEOGRAPHIC SNAPSHOT OF THE WEARABLE INJECTORS MARKET 42

4 PREMIUM INSIGHTS 43
4.1 WEARABLE INJECTORS MARKET OVERVIEW 43
FIGURE 20 SHIFT OF HEALTHCARE DELIVERY TOWARD HOMECARE DUE TO COVID-19
IS DRIVING MARKET GROWTH 43
4.2 NORTH AMERICAN WEARABLE INJECTORS MARKET, BY COUNTRY AND THERAPY 44
FIGURE 21 DIABETES SEGMENT COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020 44
4.3 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 45
FIGURE 22 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 45
4.4 WEARABLE INJECTORS MARKET: REGIONAL MIX 46
FIGURE 23 NORTH AMERICA IS THE LARGEST MARKET FOR WEARABLE INJECTORS 46

5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 24 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
5.2.1 DRIVERS 48
5.2.1.1 Shift of healthcare delivery toward homecare due to COVID-19 48
5.2.1.2 Advantages of wearable injectors in the administration of various drugs 48
5.2.1.3 Growing prevalence of chronic diseases 49
5.2.1.4 Favorable reimbursement scenario in major markets 49
5.2.1.5 Technological advancements and design development 49
5.2.2 RESTRAINTS 50
5.2.2.1 Preference for alternative drug delivery modes 50
5.2.2.2 High cost of wearable injectors 50
5.2.3 OPPORTUNITIES 50
5.2.3.1 Increasing demand for biologics and mAbs 50
FIGURE 25 US: BIOLOGIC MEDICINES IN DEVELOPMENT, 2017 51
5.2.4 CHALLENGES 51
5.2.4.1 Unfavorable reimbursement structure in developing countries 51

6 INDUSTRY INSIGHTS 52
6.1 TECHNOLOGY ANALYSIS 52
6.2 PRICING ANALYSIS 52
TABLE 2 AVERAGE SELLING PRICE: WEARABLE INJECTORS 52
6.3 VALUE CHAIN ANALYSIS 53
FIGURE 26 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS 53
6.4 ECOSYSTEM MARKET MAP 53
FIGURE 27 WEARABLE INJECTORS MARKET: ECOSYSTEM MARKET MAP 54
6.5 SUPPLY CHAIN ANALYSIS 54
FIGURE 28 WEARABLE INJECTORS MARKET: SUPPLY CHAIN ANALYSIS 55
6.6 PORTER'S FIVE FORCES ANALYSIS 56
FIGURE 29 PORTER'S FIVE FORCES ANALYSIS (2020): WEARABLE INJECTORS MARKET 56
TABLE 3 WEARABLE INJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS 56
6.6.1 THREAT OF NEW ENTRANTS 56
6.6.1.1 Growth in the overall wearable injectors market 57
6.6.1.2 Growing consolidation 57
6.6.1.3 Poor financing environment 57
6.6.2 THREAT OF SUBSTITUTES 57
6.6.3 BARGAINING POWER OF SUPPLIERS 58
6.6.4 BARGAINING POWER OF BUYERS 58
6.6.5 INTENSITY OF COMPETITIVE RIVALRY 59
6.7 REGULATORY ANALYSIS 59
6.8 PATENT ANALYSIS 60
6.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS 60
FIGURE 30 GLOBAL PATENT PUBLICATION TRENDS (2015-2020) 60
6.9 IMPACT OF COVID-19 ON THE WEARABLE INJECTORS MARKET 61

7 WEARABLE INJECTORS MARKET, BY TYPE 62
7.1 INTRODUCTION 63
TABLE 4 WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 63
7.2 ON-BODY INJECTORS 63
7.2.1 ON-BODY INJECTORS SEGMENT DOMINATED THE MARKET IN 2020 63
TABLE 5 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 64
7.3 OFF-BODY INJECTORS 64
7.3.1 OFF-BODY INJECTORS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 64
TABLE 6 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 65

8 WEARABLE INJECTORS MARKET, BY TECHNOLOGY 66
8.1 INTRODUCTION 67
TABLE 7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 67
8.2 SPRING-BASED TECHNOLOGY 67
8.2.1 SPRING-BASED TECHNOLOGY ENABLES THE DELIVERY OF DRUGS WITH HIGHER VOLUME AND VISCOSITY 67
TABLE 8 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION) 68
8.3 MOTOR-DRIVEN TECHNOLOGY 68
8.3.1 THESE DEVICES CAN GENERATE HIGH FORCE FOR SUBCUTANEOUS INJECTIONS OF HIGH-VISCOSITY LIQUIDS 68
TABLE 9 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION) 69
8.4 ROTARY PUMP TECHNOLOGY 69
8.4.1 THESE DEVICES SHOW HIGH PRECISION AND THE POSSIBILITY TO NOT ALTER THE FLUID PROPERTIES 69
TABLE 10 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION) 70
8.5 EXPANDING BATTERY TECHNOLOGY 70
8.5.1 EXPANDING BATTERY TECHNOLOGY SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 70
TABLE 11 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION) 71
8.6 OTHER TECHNOLOGIES 71
TABLE 12 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019-2026 (USD MILLION) 72

9 WEARABLE INJECTORS MARKET, BY THERAPY 73
9.1 INTRODUCTION 74
TABLE 13 WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 74
9.2 DIABETES 74
9.2.1 HIGH PREVALENCE OF DIABETES ACROSS THE GLOBE TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 74
TABLE 14 INSULIN DEVICES AVAILABLE FOR DIABETES PATIENTS 75
TABLE 15 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2019-2026 (USD MILLION) 76
9.3 IMMUNO-ONCOLOGY 76
9.3.1 IMMUNO-ONCOLOGY SEGMENT TO WITNESS NEGATIVE GROWTH DURING THE FORECAST PERIOD 76
TABLE 16 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION) 77
9.4 CARDIOVASCULAR DISEASES 77
9.4.1 CARDIOVASCULAR DISEASES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 77
TABLE 17 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD MILLION) 78
9.5 OTHER THERAPIES 78
TABLE 18 WEARABLE INJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019-2026 (USD MILLION) 79

10 WEARABLE INJECTORS MARKET, BY END USER 80
10.1 INTRODUCTION 81
TABLE 19 WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 81
10.2 HOSPITALS AND CLINICS 81
10.2.1 HOSPITALS AND CLINICS ARE THE LARGEST END USERS OF WEARABLE INJECTORS 81
TABLE 20 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2019-2026 (USD MILLION) 82
10.3 HOME HEALTHCARE SETTINGS 82
10.3.1 HOME HEALTHCARE SETTINGS SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD 82
TABLE 21 WEARABLE INJECTORS MARKET FOR HOME HEALTHCARE SETTINGS, BY COUNTRY, 2019-2026 (USD MILLION) 83

11 WEARABLE INJECTORS MARKET, BY REGION 84
11.1 INTRODUCTION 85
FIGURE 31 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 85
TABLE 22 WEARABLE INJECTORS MARKET, BY REGION, 2019-2026 (USD MILLION) 86
11.2 NORTH AMERICA 86
FIGURE 32 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT 87
TABLE 23 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 88
TABLE 24 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 88
TABLE 25 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 89
TABLE 26 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 89
TABLE 27 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 90
11.2.1 US 90
11.2.1.1 Growing IV infusion expenditure is a key factor driving the US market. 90
TABLE 28 US: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 91
TABLE 29 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 91
TABLE 30 US: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 92
TABLE 31 US: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 92
11.2.2 CANADA 92
11.2.2.1 Rising prevalence of chronic diseases in Canada to drive the demand for drugs that can be self-administered 92
TABLE 32 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 93
TABLE 33 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 94
TABLE 34 CANADA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 94
TABLE 35 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 95
11.3 EUROPE 95
FIGURE 33 EUROPE: WEARABLE INJECTORS MARKET SNAPSHOT 96
TABLE 36 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 97
TABLE 37 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 97
TABLE 38 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 98
TABLE 39 EUROPE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 98
TABLE 40 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 99
11.3.1 GERMANY 99
11.3.1.1 Availability of government support for drug development and approval to drive growth in the German wearable injectors market 99
TABLE 41 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 100
TABLE 42 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 100
TABLE 43 GERMANY: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 101
TABLE 44 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 101
11.3.2 UK 102
11.3.2.1 Government focus on biosimilar innovation to drive the market growth 102
TABLE 45 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 102
TABLE 46 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 103
TABLE 47 UK: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 103
TABLE 48 UK: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 104
11.3.3 FRANCE 104
11.3.3.1 100% coverage for diabetes by SHI to drive market growth in France 104
TABLE 49 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 104
TABLE 50 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 105
TABLE 51 FRANCE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 105
TABLE 52 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 106
11.3.4 REST OF EUROPE 106
TABLE 53 ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 107
TABLE 54 ROE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 107
TABLE 55 ROE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 108
TABLE 56 ROE: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 108
11.4 ASIA PACIFIC 108
TABLE 57 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 109
TABLE 58 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 109
TABLE 59 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 110
TABLE 60 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 110
TABLE 61 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 111
11.4.1 JAPAN 111
11.4.1.1 Large number of patients suffering from diabetes, CVD, and other chronic conditions to drive market growth in Japan 111
TABLE 62 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 112
TABLE 63 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 112
TABLE 64 JAPAN: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 113
TABLE 65 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 113
11.4.2 CHINA 113
11.4.2.1 Large diabetic population to drive market growth in China 113
TABLE 66 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 114
TABLE 67 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 114
TABLE 68 CHINA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 115
TABLE 69 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 115
11.4.3 INDIA 116
11.4.3.1 Large diabetic population to drive the market for wearable injectors in India 116
TABLE 70 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 116
TABLE 71 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 117
TABLE 72 INDIA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 117
TABLE 73 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 118
11.4.4 REST OF ASIA PACIFIC 118
TABLE 74 ROAPAC: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 118
TABLE 75 ROAPAC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 119
TABLE 76 ROAPAC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 119
TABLE 77 ROAPAC: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 120
11.5 LATIN AMERICA 120
11.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER CHRONIC CONDITIONS TO DRIVE THE MARKET IN LATIN AMERICA 120
TABLE 78 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 120
TABLE 79 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 121
TABLE 80 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 121
TABLE 81 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 122
11.6 MIDDLE EAST & AFRICA 122
11.6.1 DEMAND FOR WEARABLE INJECTORS IN THE MANAGEMENT OF DIABETES AND CVD IS EXPECTED TO INCREASE IN THE MIDDLE EAST AND AFRICA 122
TABLE 82 CONFERENCES IN THE MIDDLE EAST AND AFRICA (2016-2018) 122
TABLE 83 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019-2026 (USD MILLION) 123
TABLE 84 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 123
TABLE 85 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019-2026 (USD MILLION) 124
TABLE 86 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2019-2026 (USD MILLION) 124

12 COMPETITIVE LANDSCAPE 125
12.1 INTRODUCTION 125
FIGURE 34 KEY MARKET DEVELOPMENTS (JANUARY 2018 TO JULY 2021) 126
12.2 REVENUE ANALYSIS OF KEY MARKET PLAYERS 127
FIGURE 35 REVENUE ANALYSIS OF THE KEY PLAYERS OPERATING IN THE WEARABLE INJECTORS MARKET 127
12.3 MARKET SHARE ANALYSIS 127
FIGURE 36 WEARABLE INJECTORS MARKET SHARE, BY KEY PLAYER, 2020 128
12.4 COMPETITIVE SCENARIO 129
12.4.1 PRODUCT LAUNCHES 129
TABLE 87 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES (JANUARY 2018 TO JULY 2021) 129
12.4.2 DEALS 129
TABLE 88 WEARABLE INJECTORS MARKET: DEALS (JANUARY 2018 TO JULY 2021) 129
12.4.3 OTHER DEVELOPMENTS 130
TABLE 89 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS (JANUARY 2018 TO JULY 2021) 130
12.5 COMPETITIVE BENCHMARKING 131
12.6 COMPANY EVALUATION MATRIX 136
12.6.1 STARS 136
12.6.2 EMERGING LEADERS 136
12.6.3 PERVASIVE PLAYERS 136
12.6.4 EMERGING COMPANIES 136
FIGURE 37 WEARABLE INJECTORS MARKET: GLOBAL COMPANY EVALUATION MATRIX 137
12.7 COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS) 138
12.7.1 PROGRESSIVE COMPANIES 138
12.7.2 STARTING BLOCKS 138
12.7.3 RESPONSIVE COMPANIES 138
12.7.4 DYNAMIC COMPANIES 138
FIGURE 38 WEARABLE INJECTORS MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS 139

13 COMPANY PROFILES 140
13.1 KEY PLAYERS 140
(Business Overview, Products, Key Insights, Recent Developments, MnM View)* 13.1.1 AMGEN INC. 140
TABLE 90 AMGEN INC.: BUSINESS OVERVIEW 140
FIGURE 39 AMGEN INC.: COMPANY SNAPSHOT (2020) 141
13.1.2 MEDTRONIC PLC 144
TABLE 91 MEDTRONIC PLC: BUSINESS OVERVIEW 144
FIGURE 40 MEDTRONIC PLC: COMPANY SNAPSHOT (2020) 145
13.1.3 INSULET CORPORATION 147
TABLE 92 INSULET CORPORATION: BUSINESS OVERVIEW 147
FIGURE 41 INSULET CORPORATION: COMPANY SNAPSHOT (2020) 148
13.1.4 BECTON, DICKINSON AND COMPANY 151
TABLE 93 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 151
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 152
13.1.5 YPSOMED 154
TABLE 94 YPSOMED: BUSINESS OVERVIEW 154
FIGURE 43 YPSOMED: COMPANY SNAPSHOT (2020) 154
13.1.6 UNITED THERAPEUTICS CORPORATION 157
TABLE 95 UNITED THERAPEUTICS CORPORATION: BUSINESS OVERVIEW 157
FIGURE 44 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2020) 158
13.1.7 SUBCUJECT 160
TABLE 96 SUBCUJECT: BUSINESS OVERVIEW 160
13.1.8 ENABLE INJECTIONS 161
TABLE 97 ENABLE INJECTIONS: BUSINESS OVERVIEW 161
13.1.9 CEQUR SA 163
TABLE 98 CEQUR SA: BUSINESS OVERVIEW 163
13.1.10 SENSILE MEDICAL (A PART OF GERRESHEIMER) 164
TABLE 99 SENSILE MEDICAL: BUSINESS OVERVIEW 164
13.2 OTHER PLAYERS 165
13.2.1 STEADYMED THERAPEUTICS 165
TABLE 100 STEADYMED THERAPEUTICS: BUSINESS OVERVIEW 165
13.2.2 ATS AUTOMATION 166
TABLE 101 ATS AUTOMATION: BUSINESS OVERVIEW 166
FIGURE 45 ATS AUTOMATION: COMPANY SNAPSHOT (2020) 166
13.2.3 WEST PHARMACEUTICAL SERVICES, INC. 168
TABLE 102 WEST PHARMACEUTICAL SERVICES, INC.: BUSINESS OVERVIEW 168
FIGURE 46 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2020) 168
13.2.4 UNILIFE CORPORATION 170
TABLE 103 UNILIFE CORPORATION: BUSINESS OVERVIEW 170
13.2.5 TANDEM DIABETES CARE 171
TABLE 104 TANDEM DIABETES CARE: BUSINESS OVERVIEW 171
FIGURE 47 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2020) 171
13.2.6 VALERITAS, INC. 173
TABLE 105 VALERITAS, INC.: BUSINESS OVERVIEW 173
FIGURE 48 VALERITAS, INC.: COMPANY SNAPSHOT (2020) 173
13.2.7 BÜHLER MOTOR GMBH 175
TABLE 106 BÜHLER MOTOR GMBH: BUSINESS OVERVIEW 175
FIGURE 49 BÜHLER MOTOR GMBH: COMPANY SNAPSHOT (2020) 175
13.2.8 SONCEBOZ 177
TABLE 107 SONCEBOZ: BUSINESS OVERVIEW 177
13.2.9 NOBLE INTERNATIONAL LLC (AN APTAR PHARMA COMPANY) 178
TABLE 108 NOBLE INTERNATIONAL LLC: BUSINESS OVERVIEW 178
FIGURE 50 NOBLE INTERNATIONAL LLC: COMPANY SNAPSHOT (2020) 178
13.2.10 ELCAM DRUG DELIVERY DEVICES (E3D) 180
TABLE 109 ELCAM DRUG DELIVERY DEVICES: BUSINESS OVERVIEW 180
13.2.11 BESPAK EUROPE LTD. 181
TABLE 110 BESPAK EUROPE LTD.: BUSINESS OVERVIEW 181
FIGURE 51 BESPAK EUROPE LTD.: COMPANY SNAPSHOT (2020) 181
13.2.12 STEVANATO GROUP 183
TABLE 111 STEVANATO GROUP: BUSINESS OVERVIEW 183
13.2.13 SORREL MEDICAL 184
TABLE 112 SORREL MEDICAL: BUSINESS OVERVIEW 184
13.2.14 WEIBEL CDS 185
TABLE 113 WEIBEL CDS: BUSINESS OVERVIEW 185
13.2.15 NEUMA LLC 186
TABLE 114 NEUMA: BUSINESS OVERVIEW 186
*Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies. 14 APPENDIX 187
14.1 DISCUSSION GUIDE 187
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 190
14.3 AVAILABLE CUSTOMIZATIONS 192
14.4 RELATED REPORTS 192
14.5 AUTHOR DETAILS 193